Targeting the Alternative Complement Pathway With Iptacopan to Treat IgA Nephropathy: Design and Rationale of the APPLAUSE-IgAN Study
Dana V. Rizk(University of Alabama at Birmingham), Jonathan Barratt(University of Leicester)
Cited by 59
Related Papers
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial
|The Lancet|2023|264
Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial
|The Lancet|2023|214
The Emerging Role of Complement Proteins as a Target for Therapy of IgA Nephropathy
|Frontiers in Immunology|2019|166
Artificial intelligence and machine learning in nephropathology
|Kidney International|2020|107